Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Catherine Daum

Internal Medicine Wilmington, NC Medical Doctor

NPI 1497863476 CMS profile 112809

1124 Gallery Park Ln, Wilmington, NC 28412

Open in the dashboard

General payments

$14,524

184 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Catherine Daum of Wilmington, NC is reported in the CMS Open Payments database as having received $14,524 across 184 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $408 27
2020 General $5,851 39
2019 General $8,266 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Catherine Daum
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Catherine Daum were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Catherine Daum Internal Medicine median Middle half National median
2019 $8,266 $159 $48–$570 $163
2020 $5,851 $119 $33–$402 $114
2021 $408 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Pfizer Inc. $12,361 33 payments
  2. Novo Nordisk Inc $385 28 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $282 16 payments
  4. Amgen Inc. $233 14 payments
  5. GlaxoSmithKline, LLC. $174 14 payments
  6. Sanofi-Aventis U.S. LLC $118 9 payments
  7. Amarin Pharma Inc. $108 7 payments
  8. Lilly USA, LLC $103 8 payments
  9. AstraZeneca Pharmaceuticals LP $85 6 payments
  10. Kowa Pharmaceuticals America, Inc. $79 6 payments
  11. Other $594 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,300 4 payments
  2. Food and Beverage $2,769 172 payments
  3. Consulting Fee $2,750 2 payments
  4. Travel and Lodging $2,705 6 payments
Products named General payments · program years 2019–2021
  1. COLOGUARD $8,040 13 payments
  2. Ozempic $254 16 payments
  3. JARDIANCE Diabetes $245 13 payments
  4. Repatha $133 9 payments
  5. RYBELSUS $122 7 payments
  6. Prolia $116 6 payments
  7. TRADJENTA $113 6 payments
  8. JARDIANCE Diabetes $103 8 payments
  9. AIMOVIG $103 7 payments
  10. EVENITY $100 5 payments
  11. Other $1,912 149 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 103 drugs

Part D claims

7,035

Median for Internal Medicine: 777

Drug cost

$299,776

Median for Internal Medicine: $73,373

Branded share of claims

16%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Januvia Sitagliptin Phosphate Brand 45 $56,194
Eliquis Apixaban Brand 44 $47,466
Ozempic Semaglutide Brand 17 $30,474
Synthroid Levothyroxine Sodium Brand 213 $23,126
Xarelto Rivaroxaban Brand 11 $18,078
Mounjaro Tirzepatide Brand 16 $17,057
Horizant Gabapentin Enacarbil Brand 13 $12,954
Edarbyclor Azilsartan Med/Chlorthalidone Brand 11 $7,634
Atorvastatin Calcium Generic 670 $6,188
Metoprolol Succinate Generic 248 $4,025

The 10 drugs with the highest cost, of 103 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 78 billing codes

Paid by Medicare

$106,497

Of which drugs: $11,236

Medicare patients

441

Average age 75

Services billed

6,802

362 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 42%
Chronic kidney disease 30%
Diabetes 22%
Ischemic heart disease 21%
Depression 21%
Cancer 14%
Osteoporosis 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 25 25 $1,968

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

184 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record